The lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lupus Hub cannot guarantee the accuracy of translated content. The lupus and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lupus content recommended for you
Management approach for refractory SLE: A case study
Featured:
Betty Diamond
William Stohl
Murray Urowitz
Ricard Cervera
Manuel Francisco Ugarte-Gil
Laurent ArnaudDuring the Lupus Hub Steering Committee Meeting, held on May 7, 2024, Ricard Cervera chaired a discussion on a case study to understand the management approach for refractory systemic lupus erythematosus (SLE), with contributions from Betty Diamond, Murray Urowitz, Laurent Arnaud, William Stohl, and Manuel Francisco Ugarte-Gil.
Management approach for refractory SLE: A case study
Cervera presented a case of a 34-year-old female with a 10-year history of lupus who was hospitalized due to left arm paresthesia and speech difficulties. Her past experience with lupus nephritis, prior treatments, and comorbidities were also noted. The discussions covered differential diagnoses at hospital admission, initial tests and procedures, subsequent treatments, and final diagnosis. Cervera also shared key findings from the Euro-Phospholipid project that guided his treatment approach. The steering committee addressed several questions, including adherence to antimalarials, effective control of lupus after treatment, appropriate dosage of hydroxychloroquine, impact of steroid treatment on blood pressure, and antiphospholipid antibodies testing during diagnosis. Opinions on alternative test procedures and treatments were also shared.
